Beihai Kangcheng obtained the global authorization of the Scriptr Global Stitchr(TM) technology platform and cooperated in the development of neuromuscular disease gene therapy

Beijing and Cambridge, Massachusetts, October 25, 2021/PRNewswire/ - Beihai Kangcheng Pharmaceutical Co.

The financial terms of the cooperation agreement include advance payments, development and sales milestone payments, and royalties based on net sales

Dr.

Keith Alkek, co-founder, chairman and CEO of Scriptr Global, said: “Patients and their families suffering from dystrophin disease urgently need innovative treatments.

About dystrophin disease

Dystrophinopathy is an X-associated hereditary muscle disease, including Duchenne Muscular Dystrophy (Duchenne Muscular Dystrophy, DMD), Becker Muscular Dystrophy (BMD) and DMD-related dilated cardiomyopathy (DMD-associated dilated cardiomyopathy, DCM)

About SCRIPTR GLOBAL

Scriptr Global is a pre-clinical biotechnology company that mainly develops new treatment methods for the treatment of challenging and life-threatening diseases

For more information, please send an email to: info@scriptrglobal.

Brief Introduction of Beihai Kangcheng Pharmaceutical Co.

Beihai Kangcheng Pharmaceutical Co.

Beihai Kangcheng currently has a comprehensive and differentiated pipeline consisting of 13 pharmaceutical assets with huge market potential, targeting some of the most common rare diseases and rare tumor indications

Beihai Kangcheng strategically combines global cooperation and domestic research to establish and enrich its drug portfolio, while investing in the next generation of gene therapy technology for rare disease treatment

For more information about Beihai Kangcheng Pharmaceutical Co.